Respiratory bronchiolitis-interstitial lung disease is characteristically seen in heavy smokers, characterised by pigmented macrophages in the respiratory bronchioles and bronchocentric ground-glass opacities primarily in the lower lobes.
Description
Respiratory bronchiolitis-interstitial lung disease (RB-ILD) is a rare form of interstitial lung disease that predominantly affects smokers, typically in their third to fourth decade of life. This smoking-related interstitial lung disease is characterised by the accumulation of pigmented macrophages within respiratory bronchioles, leading to a distinctive inflammation of these small airways. It is a unique entity within the spectrum of smoking-related lung diseases, which includes conditions like desquamative interstitial pneumonia (DIP) and pulmonary Langerhans cell histiocytosis (PLCH).
Pathogenesis
The pathogenesis of RB-ILD involves the inhalation of cigarette smoke, leading to an inflammatory response in the respiratory bronchioles. This inflammation is marked by the infiltration of pigmented macrophages within these bronchioles. The accumulation of these macrophages, laden with carbon particles from tobacco smoke, contributes to the bronchiolar wall thickening and surrounding interstitial inflammation seen in RB-ILD.
Subtypes
RB-ILD is a specific subtype within the broader category of smoking-related interstitial lung diseases. Other subtypes in this category include desquamative interstitial pneumonia (DIP) and pulmonary Langerhans cell histiocytosis (PLCH).
Epidemiology, Risk Factors & Associations
- The primary risk factor for RB-ILD is heavy cigarette smoking.
- RB-ILD typically affects individuals between the ages of 30-40 years.
- There is no significant gender predilection.
Clinical Features
Patients with RB-ILD commonly present with a mild cough and dyspnoea. Physical examination may reveal end-inspiratory crackles, and spirometry typically shows a mild restrictive pattern or, less commonly, an obstructive pattern.
Complications
There’s a potential risk for progression to more severe forms of interstitial lung disease, such as DIP, although this is relatively rare. Generally, RB-ILD has a good prognosis with smoking cessation.
Pathological Features
Histopathology
- Macroscopic: The lungs may appear grossly normal or have a slightly mottled, yellow-grey appearance.
- Microscopic: Characteristically demonstrates accumulation of pigmented macrophages in respiratory bronchioles and surrounding alveolar spaces, with minimal associated cellular atypia.
Serology
There are no specific serological markers for RB-ILD.
Biochemistry
No specific biochemical markers have been identified for this condition.
Radiological Features
General Features
- Characteristically demonstrates centrilobular nodules and ground-glass opacities that are predominantly distributed in the lower lobes.
- Fine reticular changes may also be present.
- Typically lacks honeycombing, differentiating it from other interstitial lung diseases.
- Co-existing centrilobular emphysema may be present
XR
- May appear normal or show diffuse hazy opacities.
CT
- Non-contrast: Predominantly centrilobular ground-glass opacities along the bronchovascular bundles, primarily in the lower lobes. Subtle reticulation can be present, but honeycombing is typically absent.
MRI
MRI is not typically used in the evaluation of RB-ILD.
US
Ultrasonography is not typically used for the assessment of RB-ILD.
NM
- PET FDG: Generally, RB-ILD is not evaluated with PET FDG.
Grading and Staging
There is no specific grading or staging system for RB-ILD due to its non-progressive nature and its reliance on clinical and radiological correlation for diagnosis.
Diagnosis
Diagnosis typically involves a combination of clinical history, imaging, and histopathological examination. High-resolution CT is often sufficient for diagnosis when correlated with an appropriate clinical context, but lung biopsy can be performed for definitive diagnosis.
Differential Diagnosis
- Desquamative interstitial pneumonia (DIP): Presents in a similar demographic and also demonstrates ground-glass opacities. However, DIP shows a more diffuse, peripheral distribution of ground-glass opacities, as opposed to the bronchocentric/centrilobular distribution seen in RB-ILD. DIP is the most severe form of the continuum of smoking-related ILD.
- Pulmonary Langerhans cell histiocytosis (PLCH): Predominantly affects younger smokers and demonstrates a distinctive nodular and cystic pattern on imaging.
- Hypersensitivity pneumonitis: May demonstrate similar imaging findings but usually has a specific antigenic exposure history, and more upper lobe predominance.
Management
Primary management of RB-ILD involves smoking cessation, which often leads to significant improvement or resolution of symptoms. In some severe cases, corticosteroids may be utilised.